



# CDC Web Resources for Healthcare Professionals on Adult Pneumococcal Recommendations

**Miwako Kobayashi**

**Respiratory Diseases Branch**

National Adult and Influenza Immunization Summit  
July 28, 2016

# Purpose of this talk

- ACIP recommendation on PCV13 in adults aged  $\geq 65$  years introduced in September, 2014<sup>1</sup>
  - Recommendations perceived as complex
  - Requests from providers for simplified fact sheets
    - Requested by  $>80\%$  of primary care physicians in a recently conducted provider survey<sup>2</sup>
- Helpful materials have been developed by CDC and are available on the web
  - Unclear whether providers are aware and access these
  - Input needed from this group: How can we make the materials more visible, accessible, and useful?


1. Tomczyk, MMWR 2014

2. Hurley, NIC 2016

# 1. Pneumococcal vaccine timing for adults

## ■ Covers:

- Indications for both PCV13 and PPSV23 summarized in charts and in flow diagrams
- Timing of vaccinations depending on age group and presence of underlying medical conditions under various scenarios



Medical indication	Underlying medical condition	PCV13 for ≥ 19 years	PPSV23* for 19 through 64 years		PCV13 at ≥ 65 years	PPSV23 at ≥ 65 years				
		Recommended	Recommended	Revaccination	Recommended	Recommended				
None	None of the below				✓	✓ ≥ 1 year after PCV13				
Immunocompetent persons	Alcoholism		✓		✓	✓ ≥ 1 year after PCV13 ≥ 5 years after any PPSV23 at < 65 years				
	Chronic heart disease†									
	Chronic liver disease									
	Chronic lung disease§									
	Cigarette smoking									
	Diabetes mellitus									
	Cochlear implants						✓	✓	✓	✓
CSF leaks		≥ 8 weeks after PCV13		If no previous PCV13 vaccination	≥ 8 weeks after PCV13 ≥ 5 years after any PPSV23 at < 65 years					
Persons with functional or anatomic asplenia	Congenital or acquired asplenia	✓	✓	≥ 8 weeks after PCV13	✓	≥ 5 years after first dose PPSV23	✓	If no previous PCV13 vaccination	✓	≥ 8 weeks after PCV13 ≥ 5 years after any PPSV23 at < 65 years
	Sickle cell disease/other hemoglobinopathies									
Immunocompromised persons	Chronic renal failure	✓	✓	≥ 8 weeks after PCV13	✓	≥ 5 years after first dose PPSV23	✓	If no previous PCV13 vaccination	✓	≥ 8 weeks after PCV13 ≥ 5 years after any PPSV23 at < 65 years
	Congenital or acquired immunodeficiencies¶									
	Generalized malignancy									
	HIV infection									
	Hodgkin disease									
	Iatrogenic immunosuppression‡									
	Leukemia									
	Lymphoma									
	Multiple myeloma									
	Nephrotic syndrome									
	Solid organ transplant									

## 2. Recommendations, scenarios and Q&As for healthcare professionals about PCV13 for adults

- **Covers:**
  - Current adult recommendations in text and in a table
  - Common scenarios
  - Q&A

PCV13 (Pneumococcal Conjugate) Vaccine



Recommendations, Scenarios and Q&As for healthcare professionals about PCV13 for adults



Recommendations

Recommendations for Adults with no Previous Pneumococcal Vaccinations

The Advisory Committee on Immunization Practices (ACIP) recommends that all adults 65 years of age or older receive a dose of PCV13 followed by a dose of PPSV23 at least 1 year later. PCV13 and PPSV23 should not be administered on the same day. ACIP also recommends that adults 19 years of age or older with immunocompromising conditions, functional or anatomic asplenia, CSF leaks, or cochlear implants, and who have not previously received PCV13 or PPSV23, should receive a dose of PCV13 first followed by a dose of PPSV23 at least 8 weeks later (see Table 1 below). Subsequent doses of PPSV23 should follow [current PPSV23 recommendations](#) for high risk adults. Specifically, a second PPSV23 dose is recommended 5 years after the first PPSV23 dose for persons aged 19 through 64 years with functional or anatomic asplenia and for persons with immunocompromising conditions. A second dose of PPSV23 is not recommended for persons 19 through 64 years of age with cochlear implants or CSF leaks. Additionally, those who received one or more doses of PPSV23 before age 65 years for any indication should receive one final dose of the vaccine at age 65 years or older if at least 5 years have elapsed since their previous PPSV23 dose.

On this Page


- [Recommendations](#)
- [Common Patient Scenarios](#)
- [Questions and Answers](#)

Table 1: Medical conditions or other indications for administration of PCV13, and indications for PPSV23 administration and revaccination for adults 19 years of age or older

Risk Group	Underlying Medical Condition	PCV13	PPSV23*	
		Recommended	Recommended	Revaccination at 5 years after first dose
Immunocompetent persons	Chronic heart disease <sup>†</sup>		✓	
	Chronic lung disease <sup>§</sup>		✓	
	Diabetes mellitus		✓	
	CSF leaks	✓	✓	
	Cochlear implants	✓	✓	
	Alcoholism		✓	
	Chronic liver disease		✓	
	Cigarette smoking		✓	
Persons with functional or anatomic asplenia	Sickle cell disease/other hemoglobinopathies	✓	✓	✓
	Congenital or acquired asplenia	✓	✓	✓

### 3. Medscape video: “Applying the ACIP Algorithms”

- **Covers:**
  - Adult pneumococcal vaccination recommendations\* using scenarios



The screenshot shows a video player interface. On the left, a man in a suit and glasses is speaking. A blue banner below him reads "CDC Expert Commentary" and "Matthew R. Moore, MD, MPH". On the right, a light blue slide titled "Patient 1" contains the following text: "65-year-old woman", "No underlying medical conditions", "No previous pneumococcal vaccinations", "Which vaccine or vaccines should you give? BOTH!", "In what order? PCV13 first, then PPSV23", and "How much time between doses? Ideally, 6-12 months.". The video player controls at the bottom include a play/pause button, a progress bar, a volume icon, and a closed captioning (CC) icon. The video is at 03:13 / 07:38.

<http://www.cdc.gov/pneumococcal/resources/audio-video.html#videos>

\*latest as of October 2014, interval recommendations changed in June 2015

## 4. Other resources

- Matte release

<http://www.cdc.gov/vaccines/hcp/adults/downloads/matte-pneumo-hcp.docx>

- Adult immunization schedule

<http://www.cdc.gov/vaccines/schedules/hcp/adult.html>

# How can we make these resources more visible, accessible, and useful?

- Any existing channels to distribute the information?
- Useful links through partner webpages?
- Other ideas?

For more information, contact CDC  
1-800-CDC-INFO (232-4636)  
TTY: 1-888-232-6348 [www.cdc.gov](http://www.cdc.gov)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

